Multicenter evaluation of the Idylla IDH1-2 Mutation Assay Kit for detection of IDH mutational status in glioma
Virchows Archiv · 2026-11 · 489 (5) · 1149-1158
DOI: 10.1007/s00428-026-04464-8 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Virchows Archiv, online erschienen am 13.03.2026. Verfasst von Michael Jansen und 29 weiteren Autor:innen. Beteiligte Einrichtung: Neuropathology Department, Cork University Hospital, Cork, Ireland. Hauptthemen laut MEDLINE: Isocitrate Dehydrogenase, Glioma, Mutation, Brain Neoplasms. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Biocartis, University College Cork.
Abstract (Originalsprache)
The study evaluated the concordance and failure rate of the Idylla IDH1-2 Mutation Assay Kit compared to routine reference methods in real-world clinical settings using archival formalin-fixed, paraffin-embedded (FFPE) tissue, and extracted DNA from glioma patients. This was a retrospective, observational, non-interventional study conducted across 12 centers. Each site selected archived FFPE tissue ( n = 135) and extracted DNA samples ( n = 75) from glioma patients; the sets were enriched with isocitrate dehydrogenase (IDH)1-2-mutation-positive samples. All samples had previously been tested for IDH1-2 mutational status using routine reference methods and were retested using the Idylla IDH1-2 Mutation Assay Kit run on the Idylla System. Discordant results were further assessed using a third method, when available. Concordance was calculated using overall percent agreement (OPA), positive percent agreement (PPA), and negative percent agreement (NPA) values, excluding invalids and error test results. Failure rate was calculated as errors plus invalid test results on total sample set. Out of the 210 samples, reference methods had identified 111 samples with an IDH1 mutation, 18 with an IDH2 mutation, and 81 as IDH1/IDH2 wildtype. The final concordance analysis resulted an OPA of 98.51%, a PPA of 97.64%, and an NPA of 100.0%. The validity of the Idylla IDH1-2 Mutation Assay was 98.06%. The Idylla IDH1-2 Mutation Assay Kit showed comparable performance to other well-validated methods for IDH mutation analysis while demonstrating excellent assay turnaround times.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neuropathology Department, Cork University Hospital, Cork, Ireland.
- Pathology Department, Cork University Hospital, Cork, Ireland.
- Institute of Pathology, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria.
- Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, DK-2100, Denmark.
- Institute of Pathology, Klinikum Kassel, Kassel, Germany.
- Department of Pathology, Medical College of Georgia, Augusta University, Augusta, GA, USA.
Förderung
- Biocartis
- University College Cork
Zitieren
APA
Jansen, M., Dorney, M., Kraus, T. F. J., Sotlar, K., Melchior, L., Mrabet-Dahbi, S., Kolhe, R., Mondal, A. K., Vashisht, A., Favre, L., Tran, S., Mertaniemi, R., Väisänen, T., Shelestovich, N., Tabibian-Keissar, H., Shuangshoti, S., Teerapakpinyo, C., Salas-Diaz, D. A., Teixido, C., …, & Werner, R. (2026). Multicenter evaluation of the Idylla IDH1-2 Mutation Assay Kit for detection of IDH mutational status in glioma. Virchows Archiv, 489(5), 1149-1158. https://doi.org/10.1007/s00428-026-04464-8
Vancouver
Jansen M, Dorney M, Kraus TFJ, Sotlar K, Melchior L, Mrabet-Dahbi S, et al. Multicenter evaluation of the Idylla IDH1-2 Mutation Assay Kit for detection of IDH mutational status in glioma. Virchows Archiv. 2026;489(5):1149-1158. doi:10.1007/s00428-026-04464-8
BibTeX
@article{Jansen2026,
author = {Jansen, Michael and Dorney, Mairead and Kraus, Theo F J and Sotlar, Karl and Melchior, Linea and Mrabet-Dahbi, Salima and Kolhe, Ravindra and Mondal, Ashis K and Vashisht, Ashutosh and Favre, Loëtitia and Tran, Suzanne and Mertaniemi, Riikka and Väisänen, Timo and Shelestovich, Natalia and Tabibian-Keissar, Hilla and Shuangshoti, Shanop and Teerapakpinyo, Chinachote and Salas-Diaz, Daniela Alejandra and Teixido, Cristina and Lefesvre, Pierre and Sadones, Jan and Esguerra, Catalina and Magliocco, Anthony and Bollen, Lize and Weyn, Christine and De Craene, Bram and Sanna, Helen and Hand, Collette K and Burke, Louise and Werner, Reiltin},
title = {Multicenter evaluation of the Idylla IDH1-2 Mutation Assay Kit for detection of IDH mutational status in glioma},
journal = {Virchows Archiv},
year = {2026},
volume = {489},
number = {5},
pages = {1149--1158},
doi = {10.1007/s00428-026-04464-8}
}
EUVIMED